Rajesh Sehgal, MD
Hematology · Winter Park, FLNPI 1003019571
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Lilly USA, LLC at 54.4% of the total. Reporting peaked in 2023 at $2,492 and has fallen 75.5% since, to $611 in 2025.
Across 33 payments — averaging $106.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$351
- Johnson & Johnson$145
- Caris MPI, Inc.$144
- E.r. Squibb & Sons, L.L.C.$143
- Botanix SB Inc$138
- plus $679 from 14 others
What the payments were for
- Consulting fees$1,60046%
- Food & beverage$1,87854%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $1,910 |
| AstraZeneca | 3 | $351 |
| Johnson & Johnson | 2 | $145 |
| Caris MPI, Inc. | 1 | $144 |
| E.r. Squibb & Sons, L.L.C. | 2 | $143 |
| Botanix SB Inc | 1 | $138 |
| Sanofi | 1 | $129 |
| Incyte Corporation | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 3 | $80 |
| Novartis | 2 | $53 |
| Bristol Myers Squibb | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Clovis Oncology, Inc. | 2 | $35 |
| Merck | 1 | $34 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Seagen Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Tempus AI, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,509 in reported general payments places this provider in the 60th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 46 | $650,797 |
| TagrissoOsimertinib Mesylate | 16 | $270,523 |
| OrgovyxRelugolix | 60 | $162,109 |
| Abiraterone Acetate | 41 | $133,756 |
| EliquisApixaban | 87 | $78,669 |
| Anastrozole | 238 | $3,649 |
| Ondansetron OdtOndansetron | 124 | $1,770 |
| Exemestane | 13 | $1,305 |
| Tamoxifen Citrate | 53 | $975 |
| Letrozole | 73 | $849 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 68 | $813 |
| Prochlorperazine Maleate | 70 | $609 |
| Dexamethasone | 32 | $550 |
| Acyclovir | 35 | $468 |
| Duloxetine Hcl | 36 | $374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $351 | $270,52316 claims |
| PfizerEliquis | $18 | $78,66987 claims |
| Lilly USA, LLCOlanzapine | $1,910 | $14013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 79 hematology providers in Florida.
Other hematology in Winter Park
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
- Juan VarelaOrlando$131K
- Firas El ChaerMiami$105K
- Philip PancariOrlando$70K
- Melissa AlsinaTampa$64K
- Terrence BradleyMiami$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.